CAD 22,252,389.00
Reported federal agreement value. An agreement can cover several years; this is not the amount paid out.
Selected because the publisher reports recipient province NL; NL Ledger has not established the work, benefit or jurisdiction from this record; source fields are available below.
This is the whole reported commitment or notice value, not the amount paid or an NL allocation.
- Public body
- Health Canada
- Agreement start
- Nov. 26, 2024
- Program
- National Strategy for Drugs for Rare Diseases Program
- Record type
- Federal grant or contribution
Receipt
agreement 271-2025-2026-Q1-00025, amendment 1
Source location evidence
Location review incomplete.
Reported address: country: CA; province: NL; city: St. John's; postal code: A1B 4J6.
How counted: latest of 2 rows (department reports running totals). Start: 2024-11-26; end: 2027-03-31; reported: not stated. Amount: published value.
Full source fields
- _id
- 35636786
- ref_number
- 271-2025-2026-Q1-00025
- amendment_number
- 1
- amendment_date
- 2025-05-02
- agreement_type
- C
- recipient_type
- G
- recipient_business_number
- recipient_legal_name
- Government of Newfoundland and Labrador - Department of Health and Community Services
- recipient_operating_name
- research_organization_name
- recipient_country
- CA
- recipient_province
- NL
- recipient_city
- St. John's
- recipient_postal_code
- A1B 4J6
- federal_riding_name_en
- federal_riding_name_fr
- federal_riding_number
- prog_name_en
- National Strategy for Drugs for Rare Diseases Program
- prog_name_fr
- Programme de la stratégie nationale sur les médicaments pour le traitement des maladies rares
- prog_purpose_en
- Canadian Health Systems and Programs
- prog_purpose_fr
- Systèmes et programmes de santé canadien
- agreement_title_en
- 2425-HQ-000029
- agreement_title_fr
- 2425-HQ-000029
- agreement_number
- 2425-HQ-000029
- agreement_value
- 22252389.0
- foreign_currency_type
- foreign_currency_value
- agreement_start_date
- 2024-11-26
- agreement_end_date
- 2027-03-31
- coverage
- description_en
- To provide funding to willing jurisdictions to support improving access for patients with rare diseases to drugs for rare diseases, as well as improving and broadening rare disease treatments and services, to achieve better health outcomes.
- description_fr
- D'accorder des fonds aux provinces/territoires intéressés afin de favoriser l'accès aux médicaments pour le traitement des maladies rares par les patients atteints de maladies rares, de même qu’à améliorer et à élargir les traitements et services liés aux maladies rares, en vue d’obtenir de meilleurs résultats liés à la santé.
- naics_identifier
- expected_results_en
- Improved collaboration across provincial/territorial drug plans related to drugs for rare decisions decision-making. Canadians with rare diseases have better access to screening and diagnostic services they need.
- expected_results_fr
- La collaboration à l'échelle des régimes d'assurance-médicaments des provinces/territoires est améliorée en ce qui concerne la prise de décisions liées aux médicaments pour le traitement des maladies rares. Les Canadiens atteints de maladies rares bénéficient d’un meilleur accès aux services de dépistage et de diagnostic dont ils ont besoin.
- additional_information_en
- The total agreement value previously disclosed has been updated to reflect a decrease resulting from this amendment.
- additional_information_fr
- La valeur totale de l’entente précédemment divulguée a été mise à jour afin de refléter une diminution résultant de cette modification.
- owner_org
- hc-sc
- owner_org_title
- Health Canada | Santé Canada
Spot an error? Say so in the box below, or email corrections@nlledger.ca. What to send.